POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Stopped Due to COVID-19 pandemic, recruitment was temporarily put on hold. We are withdrawing this registration due to a recent amendment to the protocol that includes major changes to data elements. A new registration will be submitted for the new protocol.

Conditions

• Hemophilia A
• Factor VIII

Interventions

• DRUG: Eloctate
• DRUG: Adynovate
• DRUG: Emicizumab

Sponsor

University of Texas Southwestern Medical Center